We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.96%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$783M
AUM Growth
+$86.9M
Cap. Flow
+$43.3M
Cap. Flow %
5.53%
Top 10 Hldgs %
30.88%
Holding
120
New
12
Increased
45
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$13.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.8M
3
GKOS icon
Glaukos
GKOS
+$11.5M
4
AGN
Allergan plc
AGN
+$11.2M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$14.2M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$13.8M
3
ZBH icon
Zimmer Biomet
ZBH
+$11.6M
4
NVCR icon
NovoCure
NVCR
+$10.8M
5
BIIB icon
Biogen
BIIB
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Financials 1.39%
3 Technology 0.15%
4 Energy 0.13%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$38.1M 4.87%
3,006,862
+584,772
+24% +$7.44M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$121B
$27.4M 3.49%
180,000
+84,987
+89% +$12.8M
EXEL icon
3
Exelixis
EXEL
$13.3B
$25.4M 3.25%
1,050,000
– –
ABMD
4
DELISTED
Abiomed Inc
ABMD
$23.6M 3.02%
140,238
+34,088
+32% +$5.15M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$23.1M 2.96%
165,000
+11,000
+7% +$1.49M
CELG
6
DELISTED
Celgene Corp
CELG
$22.2M 2.83%
152,000
+10,000
+7% +$1.36M
GKOS icon
7
Glaukos
GKOS
$9.83B
$21.4M 2.73%
647,796
+302,346
+88% +$11.5M
NKTR icon
8
Nektar Therapeutics
NKTR
$2.39B
$20.8M 2.65%
57,746
+4,746
+9% +$1.48M
AGN
9
DELISTED
Allergan plc
AGN
$20.5M 2.62%
100,000
+48,000
+92% +$11.2M
ADMS
10
DELISTED
Adamas Pharmaceuticals
ADMS
$19.4M 2.47%
915,000
+546,834
+149% +$10M
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$18.6M 2.38%
1,179,900
+346,746
+42% +$5.09M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.6B
$16.7M 2.14%
179,949
-9,351
-5% -$826K
MDT icon
13
Medtronic
MDT
$109B
$16.7M 2.13%
214,115
+23,000
+12% +$1.91M
UNH icon
14
UnitedHealth
UNH
$376B
$16.6M 2.13%
85,000
-5,000
-6% -$966K
PTLA
15
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$16.1M 2.05%
297,400
+186,595
+168% +$11M
ESPR
16
DELISTED
Esperion Therapeutics
ESPR
$15.6M 2%
311,803
-51,544
-14% -$2.49M
ESRX
17
DELISTED
Express Scripts Holding Company
ESRX
$15.5M 1.98%
245,000
+89,000
+57% +$5.53M
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
$14.5M 1.85%
+569,491
New +$13.1M
INCY icon
19
Incyte
INCY
$24.2B
$13.4M 1.71%
115,000
-25,046
-18% -$3.17M
NVCR icon
20
NovoCure
NVCR
$1.73B
$13.2M 1.69%
666,528
-549,786
-45% -$10.8M
GILD icon
21
Gilead Sciences
GILD
$162B
$12.6M 1.61%
155,551
-101,365
-39% -$7.75M
ABBV icon
22
AbbVie
ABBV
$443B
$12.4M 1.59%
140,000
+5,000
+4% +$381K
JAZZ icon
23
Jazz Pharmaceuticals
JAZZ
$15.9B
$12.4M 1.59%
85,000
-20
-0% -$3.02K
NVRO
24
DELISTED
NEVRO CORP.
NVRO
$11.8M 1.51%
130,000
-25,118
-16% -$2.15M
CNC icon
25
Centene
CNC
$30.7B
$10.6M 1.36%
220,000
+20,000
+10% +$861K
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Rhenman & Partners Asset Management held 120 positions worth $783M, up 12% from $696M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $43.3M of net new capital in Q3 2017, opening 12 new positions and adding to 45 existing holdings. Its largest new stake was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Pfizer, an estimated $14.2M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2017 buy was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.
  • Rhenman & Partners Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $12.8M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2017 reduction was Pfizer, cutting an estimated $14.2M.
  • Rhenman & Partners Asset Management fully exited NeuroDerm Ltd. Ordinary Shares in Q3 2017, selling an estimated $13.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $783M portfolio in Q3 2017.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 26 in Q3 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $783M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.